Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease

Pharmaceutical Research

Volumn 21, Issue 5, 2004, Pages 736-741

  Lee, Minhyung ^a   Bikram, Malavosklish ^b   Oh, Seungjoon ^c   Bull, David A ^d   Sung, Wan Kim ^b  

^a Inha University School of Medicine   (South Korea)

^b UNIVERSITY OF UTAH   (United States)

^c Kyung Hee University Hospital   (South Korea)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Hypoxia; RTP801; Sp1; Transcriptional regulation; Vascular endothelial growth factor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CIS ACTING ELEMENT; LUCIFERASE; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; ASSAY; CONTROLLED STUDY; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE INSERTION; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; ISCHEMIA; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION;

CELL LINE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; LUCIFERASES; PLASMIDS; PROMOTER REGIONS (GENETICS); SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3543020981     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000026421.09367.b3     Document Type: Article

References (23)

1. M. Azrin. Angiogenesis, protein and gene delivery. Br. Med. Bull. 59:211-215 (2001).
2. J. Kastrup, E. Jorgensen, and V. Drvota. Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium. Therapeutic angiogenesis. Scand. Cardiovasc. J. 35:291-296 (2001).
3. J. M. Isner. Myocardial gene therapy. Nature 415:234-239 (2002).
4. J. F. Symes, D. W. Losordo, P. R. Vale, K. G. Lathi, D. D. Esakof, M. Mayskiy, and J. M. Isner. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68:836-837 (1999).
5. P. R. Vale, D. W. Losordo, C. E. Milliken, M. Maysky, D. D. Esakof, J. F. Symes, and J. M. Isner. Left ventricular electrome-chanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102:965-974 (2000).
6. C. Sylven, N. Sarkar, A. Ruck, V. Drvota, S. Y. Hassan, B. Lind, A. Nygren, Q Kallner, P. Blomberg, J. van der Lindern, D. Lindblom, L. A. Brodin, and K. B. Islam. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron. Artery Dis. 12:239-243 (2001).
7. D. G. Affleck, L. Yu, D. A. Bull, S. H. Bailey, and S. W. Kim. Augmentation of myocardial transfection using TerplexDNA: a novel gene delivery system. Gene Ther. 8:349-353 (2001).
8. M. Lee, J. Rentz, S. Han, D. A. Bull, and S. W. Kim. Water soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther. 10:585-593 (2003).
9. E. Brogi, G. Schatteman, T. Wu, E. A. Kim, L. Varticovski, B. Keyt, and J. M. Isner. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J. Clin. Invest. 97:469-476 (1996).
10. J. S. Lee and A. M. Feldman. Gene therapy for therapeutic myocardial angiogenesis: a promising synthesis of two emerging technologies. Nature Med. 4:739-742 (1998).
11. M. L. Springer, A. S. Chen, P. E. Kraft, M. Bednarski, and H. M. Blau. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 2:549-558 (1998).
12. R. J. Lee, M. L. Springer, W. E. Blanco-Bose, R. Shaw, P. C. Ursell, and H. M. Blau. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102: 898-901 (2000).
13. M. Lee, J. Rentz, M. Bikram, S. Han, D. A. Bull, and S. W. Kim, Hypoxia inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther. 10:1535-1542 (2003).
14. H. Su, J. Arakawa-Hoyt, and Y. W. Kan. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc. Natl. Acad. Sci. USA 99:9480-9485 (2002).
15. T. Shoshani, A. Faerman, I. Mett, E. Zehn, T. Tenne, S. Corodin, Y. Moshel, S. Elbaz, A. Budanov, A. Chajut, H. Kalinski, I. Kamer, A. Rozen, O. Mor, E. Keshet, D. Leshkowitz, P. Einat, R. Skaliter, and E. Feinstein. Identification of a novel hypoxiainducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22:2283-2293 (2002).
16. 2 tension. Proc. Natl. Acad. Sci. USA 92: 5510-5514 (1995).
17. R. H. Wenger and M. Gassmann. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem. 378:609-616 (1997).
18. B.-H. Jiang, E. Rue, G. L. Wang, R. Roe, and G. L. Semenza. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271:17771-17778 (1996).
19. G. L. Semenza, B. H. Jiang, S. W. Leung, R. Passantino, J. P. Concordet, P. Maire, and A. Giallongo. Hypoxia response elements in the aldolase A. enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271:32529-32537 (1996).
20. G. L. Wang and G. L. Semenza. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 90:4304-4308 (1993).
21. Q. Xu, Y.-S. Ji, and J. F. Schmedtje Jr. Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. J. Biol. Chem. 275:24583-24589 (2000).
22. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95:7987-7992 (1998).
23. T. Sanchez-Elsner, L. M. Botella, B. Velasco, C. Langa, and C. Bernabeu. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth pathways. J. Biol. Chem. 277:43799-43808 (2002).